

Rupesh Kotecha¹, Omer Gal¹, Eshan Patel², Michael Craig³, Simon Khagi⁴, Kimberly Ku⁵
¹Miami Cancer Institute, Miami, FL, USA, ²Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA, ³Mon Health Cancer Center, Morgantown, WV, USA, ⁴Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA, ⁵Illinois CancerCare, Bloomington, IL, USA
Correspondence: rupeshk@baptisthealth.net

INTRODUCTION

- **Tumor Treating Fields (TTFields)** are frequency-specific alternating electric fields
 - Disrupt mitosis of cancer cells¹
 - May elicit a downstream antitumor immune effect²
- FDA-approved in 10/2024 for the treatment of metastatic non-small cell lung cancer (mNSCLC)
- Overall survival benefit reported in the phase III LUNAR study³
- **The objective of this analysis was to report the following outcomes for patients treated in the United States post-FDA approval:**
 - **Demographics**
 - **Usage**
 - **Systemic therapy**

METHODS

- Data were collected from the device-manufacturer database for patients with mNSCLC that:
 - Progressed on or after platinum-based therapy
 - Were prescribed TTFields by a certified prescriber
- Baseline patient characteristics and treatment details were collated
- **Usage was calculated for those who had used the device for at least one month**

DISCUSSION AND CONCLUSION

- Actionable Take Away Message**
- Growth in TTFields uptake was observed after FDA-approval for patients with mNSCLC
 - Most patients were treated with an immune-checkpoint inhibitor (ICI)
 - Usage patterns appear similar to those observed in the phase III LUNAR study
- Future Direction for Research**
- Further patterns of use and toxicity data will be important to assess utility and benefit of TTFields with contemporary systemic therapies of mNSCLC in real life clinical practice

REFERENCES

¹Giladi, M et al. Scientific Reports 2015, doi:10.1038/srep18046
²Voloshin, T et al. Cancer Immunology, Immunotherapy 2020, doi:10.1007/s00262-020-02534-7
³Leal, T et al. The Lancet Oncology 2023, doi:10.1016/S1470-2045(23)00344-3


RESULTS

- The data cutoff window for this analysis was March 7, 2025
- A total of 91 patients were prescribed TTFields
- 62 patients (68%) were able to start TTFields

Patient and Treatment Characteristics (N=62)


Variable	N (%)
Age at Diagnosis, median (IQR)	66 (60-72)
Sex	
Female	34 (55)
Male	28 (45)
Histology	
Adenocarcinoma	43 (69)
Squamous cell carcinoma	16 (26)
Other	3 (5)
Concurrent systemic therapy	
Docetaxel-based	27 (44)
ICI	32 (52)
Both	3 (5)
ICI used in any treatment line	
Yes	58 (94)
No	4 (6)
TTFields usage, median hours per day (IQR, N=32)	12 (9-16)

Prescribing Provider (N=91)




Provider	N	%
Medical Oncologist	67	74%
Radiation Oncologist	19	21%
Other Disciplines	5	5%

Number of NSCLC patients per month prescribed TTFields



Period (month)	Number of new patients
10-11/2024	13
11-12/2024	18
12/2024-1/2025	16
1-2/2025	20
2-3/2025	23

Treatment setting (N=91)



Setting	N	%
Community Hospital	70	77%
Academic Center	21	23%